Ghost Tree Capital »

An2 Therapeutics shares owned by Ghost Tree Capital

Quarter-by-quarter ownership of An2 Therapeutics (ANTX) shares owned by Ghost Tree Capital from 13F filings

Historical chart of Ghost Tree Capital investment in An2 Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including An2 Therapeutics held by Ghost Tree Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in An2 Therapeutics by Ghost Tree Capital

Quarter filed Position value Share count Share price at filing
2024-06-30 $472k 219k 2.15
2024-03-31 $713k 219k 3.25

More positions owned by Ghost Tree Capital

Alnylam Pharmaceuticals (ALNY)
Insmed Com Par $.01 (INSM)
Biohaven (BHVN)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Soleno Therapeutics (SLNO)
Axsome Therapeutics (AXSM)
Ascendis Pharma A/s Sponsored Adr (ASND)
Vaxcyte (PCVX)
Crinetics Pharmaceuticals In (CRNX)
Roivant Sciences SHS (ROIV)
Perspective Therapeutics Com New
Tg Therapeutics (TGTX)
Sarepta Therapeutics (SRPT)
Cg Oncology (CGON)
Corbus Pharmaceuticals Hldgs Com New (CRBP)

View all positions for Ghost Tree Capital

Top funds holding An2 Therapeutics

RA Capital Management
Octagon Capital Advisors
Frazier Life Sciences Management
TCG Crossover Management
Citadel Advisors
Henderson Group
Vanguard Group
Millennium Management
Adage Capital Partners GP
BlackRock
Goldman Sachs Group
Ghost Tree Capital
Geode Capital Management
Two Sigma Advisers
Walleye Trading Advisors

View all funds holding An2 Therapeutics